FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileNeumora Therapeutics, Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
Back to Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock (NMRA) analyst ratings and price targets

The latest rating and price-target changes from Wall Street analysts, newest first — the firm, the analyst, and the article each one was published in.

Average 12-month target $5.67 · Consensus Buy (6 analysts)

Firm · analystDateRatingPrice targetSource
RBC CapitalBrian AbrahamsJul 13, 2026MaintainsOutperform$5.00from $7.00TheFly ↗
Mizuho SecuritiesJun 18, 2026MaintainsOutperform$4.00from $6.00TheFly ↗
HC Wainwright & Co.Jun 16, 2026MaintainsBuy——
NeedhamJun 16, 2026MaintainsBuy——
NeedhamMar 31, 2026MaintainsBuy——
GuggenheimMar 31, 2026MaintainsBuy——
William BlairFeb 17, 2026UpgradeMarket Perform → Outperform——
Leerink PartnersMarc GoodmanJan 12, 2026—$8.00TheFly ↗
Mizuho SecuritiesGraig SuvannavejhJan 5, 2026—$6.00from $20.00StreetInsider ↗
RBC CapitalDec 1, 2025UpgradeSector Perform → Outperform$7.00from $4.00TheFly ↗
StifelNov 17, 2025MaintainsHold——
NeedhamOct 28, 2025MaintainsBuy$8.00from $23.00TheFly ↗
GuggenheimOct 27, 2025UpgradeNeutral → Buy——
JP MorganSep 16, 2025DowngradeNeutral → Underweight——
MizuhoJul 16, 2025MaintainsOutperform——

Source: Wall Street analysts' published price targets and ratings, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 22, 2026. Not FRC research or a recommendation.